Edition:
India

Anika Therapeutics Says Trial Of Knee Osteoarthritis Drug Misses Main Goal


Wednesday, 20 Jun 2018 

June 19 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM CINGAL 16-02 CLINICAL TRIAL IN KNEE OSTEOARTHRITIS.ANIKA THERAPEUTICS INC - CINGAL 16-02 STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE AT PRIMARY ENDPOINT OF 26 WEEKS.ANIKA-CINGAL ACHIEVED GREATER PAIN REDUCTION NUMERICALLY AT EVERY TIME POINT IN STUDY, DIFFERENCE AT 26-WEEKS DID NOT REACH STATISTICAL SIGNIFICANCE.ANIKA-STRONG PAIN REDUCTION,OVERALL SYMPTOM RELIEF CONSISTENT WITH STATISTICALLY SIGNIFICANT RESULTS OF CINGAL 13-01 PHASE III PLACEBO-CONTROLLED STUDY. 

Company Quote

55.91
 --
23 Aug 2019